Digoxin & Verapamil Interaction

Verapamil (Calan, Verelan) significantly increases digoxin (Lanoxin) serum concentrations, typically by 50-75%, creating a high risk of digoxin toxicity — a potentially fatal condition causing cardiac arrhythmias, nausea, visual disturbances, and confusion ^[1]. This interaction has been recognized since the early 1980s and is one of the most well-documented and clinically significant drug interactions in cardiology ^[2]. Both medications are used in the management of cardiac conditions, particularly atrial fibrillation, making co-prescription common despite the interaction risk ^[3].

Digoxin has a narrow therapeutic index (target serum concentration 0.8-2.0 ng/mL), meaning small changes in drug levels can shift a patient from therapeutic benefit to dangerous toxicity ^[1]. The combination of verapamil's pharmacokinetic effect (raising digoxin levels) and its pharmacodynamic effect (additive suppression of cardiac conduction) creates a dual hazard that requires careful dose adjustment and monitoring ^[2].

Verapamil increases digoxin serum concentrations through multiple mechanisms ^[1]. First, verapamil inhibits P-glycoprotein (P-gp), a transmembrane efflux transporter expressed in the intestinal epithelium, renal tubular cells, and hepatic canaliculi ^[2]. Inhibition of intestinal P-gp increases digoxin oral bioavailability from approximately 70% to over 85% ^[2]. Inhibition of renal P-gp reduces digoxin tubular secretion, decreasing renal clearance by approximately 25-35% ^[1]. Inhibition of hepatobiliary P-gp reduces digoxin excretion into bile ^[2]. The net effect is a 50-75% increase in steady-state digoxin serum concentrations within 7-14 days of starting verapamil ^[1].

Beyond pharmacokinetics, there is an important pharmacodynamic interaction: both digoxin and verapamil slow conduction through the atrioventricular (AV) node ^[3]. Digoxin increases vagal tone and directly depresses AV nodal conduction, while verapamil blocks L-type calcium channels essential for AV nodal conduction ^[3]. Their combined effect can produce excessive AV block (second-degree or third-degree heart block), severe bradycardia, and potentially asystole ^[1].

Digoxin toxicity affects approximately 1% of hospitalized patients on digoxin and carries a mortality rate of 3-7% ^[1]. Toxic manifestations include: cardiac arrhythmias (particularly bidirectional ventricular tachycardia, accelerated junctional rhythm, atrial tachycardia with block, severe bradycardia), gastrointestinal symptoms (nausea, vomiting, anorexia, abdominal pain), neurological symptoms (confusion, lethargy, delirium), and visual disturbances (yellow-green color vision changes, blurred vision, halos) ^[2]. In the pre-awareness era, before the interaction was widely recognized, numerous cases of fatal cardiac arrhythmias were attributed to verapamil-induced digoxin toxicity ^[3]. Risk factors for toxicity include: renal impairment (digoxin is 60-80% renally cleared), hypokalemia (increases myocardial sensitivity to digoxin), hypomagnesemia, hypothyroidism, advanced age, and small body mass ^[1]. Even with appropriate dose reduction, the pharmacodynamic interaction (additive AV nodal suppression) persists and can cause symptomatic bradycardia at digoxin levels within the 'therapeutic' range ^[3].

When initiating verapamil in a patient already on digoxin, reduce the digoxin dose by 33-50% prospectively ^[1]. For example, if the patient takes digoxin 0.25 mg daily, reduce to 0.125 mg daily when starting verapamil ^[2]. Check a digoxin serum level 7-10 days after starting verapamil (time to reach new steady state) and adjust further based on levels and clinical response ^[1]. Target digoxin serum concentration of 0.5-0.9 ng/mL when used with verapamil (lower end of therapeutic range) ^[2]. Monitor heart rate and rhythm closely — obtain an ECG at baseline and after dose stabilization ^[3]. If the combination is being newly initiated for atrial fibrillation rate control, consider whether single-agent therapy with either drug alone might suffice, or whether alternative rate-control strategies are available ^[1]. Educate patients about symptoms of digoxin toxicity: nausea, loss of appetite, visual changes, confusion, palpitations, slow or irregular heartbeat ^[2].

Check digoxin serum level at baseline, 7-10 days after starting verapamil, and at any dose change of either medication ^[1]. Target trough digoxin level 0.5-0.9 ng/mL; levels above 2.0 ng/mL are associated with significantly increased toxicity risk ^[2]. Obtain an ECG at baseline and periodically to assess PR interval, heart rate, and for signs of digoxin toxicity (ST-segment scooping, T-wave changes, arrhythmias) ^[3]. Monitor serum potassium and magnesium, as hypokalemia and hypomagnesemia enhance digoxin toxicity ^[1]. Renal function (serum creatinine, eGFR) should be assessed regularly, as declining renal function reduces digoxin clearance and further raises levels ^[2]. Heart rate monitoring at home (resting heart rate, ideally via pulse check or wearable device) can help detect developing bradycardia between office visits ^[3]. If the patient reports nausea, visual changes, confusion, or palpitations, obtain a stat digoxin level and ECG ^[1].

For rate control of atrial fibrillation without digoxin, beta-blockers (metoprolol, atenolol) provide AV nodal suppression without the P-glycoprotein-mediated drug interaction ^[1]. Diltiazem is another calcium channel blocker that also raises digoxin levels but to a lesser degree (20-30% increase versus 50-75% with verapamil) — it is still not free of interaction but is modestly safer ^[2]. If digoxin is essential and calcium channel blockade is needed for hypertension, amlodipine (a dihydropyridine) does not significantly affect AV nodal conduction and has minimal effect on digoxin levels ^[3]. For heart failure patients on digoxin who need rate control, beta-blockers (carvedilol, bisoprolol, metoprolol succinate) are guideline-directed therapies that serve dual purposes ^[1]. If both digoxin and verapamil are deemed necessary, the dose reduction and monitoring strategy described above should be rigorously followed ^[2].